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Objective: To evaluate the ability of Canadian laboratories to identify enterococci and detect low-level resistance to 
penicillin, ampicillin and vancomycin in five provinces and two territories by two external quality assessment schemes. 
Methods: Enterococcus faecium, strain D366, with minimum inhibitory concentrations for vancomycin and penicillin 
of 32 and 16 mg/L respectively, was distributed during a routine proficiency survey. Laboratories were required to culture 
and identify the isolate and to test antimicrobial susceptibility. Participants were assessed against consensus reference 
values. 
Results: Three hundred and sixty-four hospital, commercial and public-health laboratories participated, using their 
established procedures for patient samples. The isolate was identified to the species level by 222 (61%) laboratories and 
to the genus level by a further 98 participants. Forty-four failed to meet the expected standard. Vancomycin resistance 
was detected by 94%. Those reporting a falsely susceptible result used disk diffusion testing. Penicillin resistance was 
noted by 250 of 258 laboratories reporting on this agent. An incorrect ampicillin-susceptible finding was reported by 62 
of 147 laboratories using automated microdilution or agar dilution methods. 
Conclusions: Most laboratories identified the isolate to an appropriate level. Detection of low-level vancomycin and 
penicillin resistance was achieved by the majority. Ampicillin resistance was less readily detected. 
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INTRODUCTION 
The increasing prevalence of Enterococcus species in 
hospital-acquired infections has been well documented 
[l-31. In the USA, enterococci are the third most 
common cause of nosocomial bacteremias and the 
second most common cause of nosocomial surgical 
wound and urinary tract infections [4,5]. Concomitant 
with the increasing profile of Enterococcusfaecalis and E. 
faecium is the increase in the resistance of these 
organisms to multiple antimicrobial agents. Resistance 
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to penicillin and ampicillin [6-81, with or without the 
production of p-lactamase, and high-level resistance to 
aminoglycosides [9-113 has created a significant 
challenge. Of greatest concern is the emergence of 
vancomycin-resistant enterococci (VRE) documented 
in Europe [12-141 and the USA [15-171 since the late 
1980s. Documented failure of laboratories to detect 
resistance to ampicillin and vancomycin in enterococci 
creates an additional cause for concern [18-201. 
The ability of laboratories in Canada to identify 
enterococci to the species level and to detect low-level 
resistance to penicillin, ampicillin and vancomycin was 
assessed by the Laboratory Proficiency Testing Program 
(LPTP) in Ontario and the Clinical Microbiology 
Members, LPTP Microbiology Committee: J. Gun-Munro, 
R. Lannigan, D. E. Low, D. Thompson, M. Treloar. 
Members, CMPT Microbiology Committee: D. Church, 
A. Clarke, G. Horsman, P. Kibsey, A. Kwong, R. Rennie, 
D. Roscoe, G. Webb, J. Wilson. 
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Proficiency Testing (CMPT) program of the University 
of British Columbia. A strain of E. faecium resistant to 
penicillin and vancomycin was distributed as a routine 
external quality assessment challenge to all micro- 
biology laboratories in five provinces and the two 
territories. 
METHODS 
Study protocol 
E. faecium D366 was selected as the challenge organism 
on the basis of its resistance to vancomycin [21], due to 
the vunB gene, and minimal inhibitory concentrations 
(MICs) for vancomycin and penicillin of 32 mg/L and 
16 mg/L respectively. It was distributed by the LPTP 
as one of four lyophilized cultures sent to the 192 
laboratories in Ontario licensed for bacteriologic 
testing of human specimens. The clinical information 
accompanying the isolate stated that it was from a blood 
culture. Participating laboratories were required to 
identify and perform susceptibility tests on the 
challenge organism, using the routine laboratory 
procedures for simdar patient specimens. Laboratories 
were expected to test and report appropriate antibiotics 
according to those listed in the National Committee for 
Clinical Laboratory Standards’ (NCCLS) documents, 
M100-S5 [22], M2-A5 [23] and M7-A3 [24], for 
the organism/site based on the clinical information 
provided. Interpretive categories of susceptible (S), 
intermediate (I) and resistant (R) but neither the 
specific zone size diameters nor the MICs were 
reported and evaluated. The turnaround time from 
the survey start date to the due date for results was 
12 days. 
The CMPT distributed the same strain to 174 
laboratories in four provinces and two territories. The 
organism was commercially prepared for transport 
using a Culti-loops format (Chrisope Technologies 
Inc., Lake Charles, LA, USA). The refrigerated shelf 
life of the preparation was 1 year. The time between 
shipping and receipt did not exceed 48 h. Standard pro- 
cedure for the reconstitution was required. Participants 
were required to isolate and identify the organism and 
to perform designated antimicrobial susceptibility tests. 
Reference results 
The LPTP designated seven laboratories to carry out 
pre-survey analysis of the challenge material and to 
provide reference values for identification of the isolate 
and susceptibility results. These reference laboratories 
are operated by the LPTP Microbiology Committee 
members and by the London Health Science Centre, 
University Campus, London, Ontario. Identification 
by the reference laboratories was performed using 
conventional biochemical testing and by using the 
Vitek, Microscan and API 20s systems. Disk diffusion 
testing was performed by six reference laboratories, 
according to NCCLS guideline M2-A5 [23]. Mueller- 
Hinton agar and commercially available antibiotic disks 
were required to be used. Six reference laboratories 
determined the MIC values with a variety of com- 
mercial systems, including Microscan, Vitek and 
Sensititre. A tube macrodilution MIC for ampicillin 
and penicillin was determined by one of the reference 
laboratories because of the discrepancy between the 
results of disk diffusion and MIC testing by the 
automated systems. One reference laboratory also 
determined the MIC for ampicillin with the Etest. 
CMPT reference values were derived from 13 
user-group laboratories from teaching and large 
community hospitals. Within the reference group, the 
routine testing systems are similar to those described for 
the LPTP. Eighty per cent consensus agreement on the 
reference value is required before the sample is 
considered acceptable for evaluation of performance. 
Data collection, review and analysis followed the 
established independent processes of the LPTP and 
CMPT [25]. 
RESULTS 
Identification 
The reference laboratories agreed that the challenge 
isolate was E.faecium. The expected standard of perfor- 
mance by the participants was correct identification of 
the species or identification to the correct genus with 
referral to another laboratory for further identification. 
Of the 364 laboratories that reported results on this 
challenge, 222 (61%) correctly identified the isolate to 
the species level. A further 98 (26.9%) identified it to 
the genus level but not to the species level. The 
remaining 44 laboratories failed to meet the expected 
standard: 19 identified the organism as E. faeculis, and 
25 (6.9%) failed to recognize it as an enterococcus. The 
performance by LPTP participants, as shown in Table 
1, was better (p<O.Ol) than that of CMPT participants, 
because only 15 of 190, compared to 29 of 174, did not 
meet the expected standard for identification. None of 
the participating laboratories misidentified the isolate as 
E. gallinarum or E. casselijlavus. 
The CMPT participating laboratories are divided 
into A, B and C categories based on a program- 
developed formula that takes into account service 
specimen load and weighted values for different speci- 
men types. Category A includes full service laboratories 
performing many complex procedures, while category 
C laboratories are small facilities processing fewer than 
1200 samples per year-predominantly urine and 
426  Cl in ica l  M ic rob io logy  and In fect ion,  Volume 5 Number  7,  July  1999 
Table 1 Identification reported by participating laboratories 
Correct ID Incorrect ID 
Species Genus E.  faecalis Not enterococcus 
No. (%) No. (%) No. (%) No. (%) 
fdl (n=364) 
By scheme 
CMPT (n=174) 
LPTP (n=190) 
By method 
Vitek 
Microscan 
API UniScept 
Sceptor 
Classical 
222 (61) 
101 (58) 
121 (63.7) 
60 (27a) 
64 (28.8) 
30 (13.5) 
53 (23.9) 
10 (4.5) 
98 (26.9) 
44 (25.3) 
54 (28.4) 
0 
0 
0 
2 (2) 
94 (97.9) 
19 (5.2) 
10 (5.7) 
9 (4.7) 
0 
1 (5.3) 
1 (5.3) 
1 (5.3) 
16 (84.2) 
25 (6.9) 
19 (10.9) 
6 (3.2) 
a The number of participating laboratories by method expressed as a percentage of all laboratories reporting the identification category. 
throat cultures. Category B laboratories cover the 
intermediate range. 
The CMPT participants included 64 category A, 
73 category B and 37 category C laboratories. Of the 
category A group, 57 correctly identified the species, 
as did 40 of category B, but only four of category C. 
Thirty-two per cent of category B and 66.6% of 
category C laboratories correctly identified the genus. 
The LPTP does not strati+ participants by complexity 
of operations, but most laboratories reporting only at 
the genus level would fit into the CMPT category B. 
Laboratories used a variety of methods to achieve 
correct species identification. Twenty-six CMPT parti- 
cipants and 37 LPTP laboratories used the Vitek 
system, 26 and 34 respectively used one of the 
Microscan systems, and 13 and 16 respectively used an 
API strip. Only five LPTP participants used classical 
biochemical methods, in comparison to 28 &om the 
CMPT program. Of the 19 laboratories that in- 
correctly identified the challenge as E. faecalis, 17 used 
classical biochemical methods, one used a Microscan 
Table 2 Vancomycin susceptibility results by method 
No. (%) of laboratories reporting 
~ ~ ~~ 
Resistant' Intermediate Susceptible 
All methods 
(n=326) 307 (94.2) 12 (3.7) 7 
Disk &sion 146/307 (47.6) 8 (66.6) 7 (100) 
i%croScan 48 (15.6) 4 (33.3) 0 
Vitek 49 (16.0) 0 0 
API UniScept 33 (10.7) 0 0 
Agar ddution 7 (2.3) 0 0 
Other 24 (7.8) 0 0 
'Expected result. 
system and one used the Sceptor system. Some labor- 
atories reported E. faecalis on the basis of a positive bile 
esculin result and growth in the presence of 6.5% NaC1. 
Susceptibility testing 
The reference laboratories reported disk diffusion zone 
size diameters and MIC determinations for vanco- 
mycin, penicillin and ampicillin. By consensus agree- 
ment, the challenge isolate of strain D366 was resistant 
to vancomycin (MIC 232 mg/L) and penicilhn (MIC 
16 mg/L) regardless of the method used. The reference 
results for ampicillin varied (MIC 4-16 mg/L) and no 
consensus was achieved. Minimum inhibitory concen- 
trations for ampicillin, with the exception of that 
determined by tube macrodilution, and one disk 
diffusion result, fell within the susceptible interpretive 
category by NCCLS criteria (zone diameter 217 mm, 
MIC (8 mg/L). The remaining reference values fell 
into the intermediate or resistant categories. The 
reference laboratory that performed the tube macro- 
dilution test noted a clearcut endpoint for penicillin but 
a tailing, difficult-to-read, endpoint for ampicillin. 
Of the 364 total participating laboratories, 326 
recorded a result for vancomycin with 94.2% correctly 
detecting the vancomycin resistance. Only seven 
laboratories recorded a susceptible finding, with a 
further 12 reporting an intermediate result, although 
three of these actually recorded the result as moderately 
susceptible. The methods used are shown in Table 2. 
Very few CMPT participants used ampicillin to 
test for p-lactam antibiotic resistance, whereas 147 of 
190 LPTP laboratories recorded an ampicillin result. Of 
the LPTP laboratories reporting ampicillin, only 84 
considered the isolate to be resistant. Forty-two per 
cent (57 of 147) reported it as susceptible, and a further 
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Table 3 Ampicdlin results by method reported by LPTP participants 
No. (YY) of laboratories 
Resistant Intermediate Susceptible Total 
All methods 84 (57.1) 6 (4.1) 57 (38.8) 147 
Agar dilution 7 (8.3) 0 6 (10.5) 13 
MicmScan 2 (2.4) 1 (16.6) 23 (40.4) 26 
Disk diffusion 57/84 (67.9) 4 (66.6) 12 (21.0) 73 
API UniScept 1 (1.2) 1 (16.6) 3 (5.3) 5 
Vitek 13 (15.5) 0 11 (19.3) 24 
Other microdilution 4 (4.8) 0 2 (3.5) 6 
six reported an intermediate finding, although two 
actually recorded moderately susceptible. The distri- 
bution of ampicillin results by the testing method used 
is shown in Table 3. 
Ninety-seven LPTP participants and 161 from the 
CMPT recorded a result for penicillin. Of the 258 
reports, 250 (97%) recorded resistance. Only eight 
laboratories found the strain to be penicillin susceptible. 
Of these, two were Microscan users and the method 
code was not recorded for the others. There were no 
intermediate results. Six laboratories noted incorrectly 
that the strain was P-lactamase-producing, while 282 
agreed with the negative reference finding. Seventy-six 
(20.9%) did not record a p-lactamase result. 
DISCUSSION 
Rapid isolation, identification and antimicrobial 
susceptibility testing of pathogenic enterococci is 
mandatory in all laboratories handling specimens from 
serious infections, given the species-specific differences 
in susceptibility to p-lactam and glycopeptide anti- 
biotics and the clinical significance of vancomycin- 
resistant, ampicillin-resistant strains [26]. 
Canadian laboratories serving the majority of the 
population do meet this requirement. Over 60% of 
those assessed by our survey were able to correctly 
identify the challenge strain of E. faecium. A further 
27% identified it correctly to the genus level and 
indicated referral to another laboratory for additional 
investigation. Laboratories choosing to limit identi- 
fication to the genus were smaller community hospital 
facilities or less sophisticated private sector laboratories. 
Identification to the species level was most commonly 
achieved with one of the commercial identification 
systems. Failure to identify to this level was due to the 
use of a limited range of classical biochemical tests 
lacking the discriminatory power for species identi- 
fication. Smaller laboratories tended to overinterpret 
the biochemical results. 
Laboratories participating in our survey had no 
difficulty in detecting the low-level vancomycin 
resistance of E. faeciurn D366, regardless of the wide 
range of susceptibility testing methods used. In 
contrast, an earlier study showed that 71% of labora- 
tories failed to detect vancomycin resistance in a strain 
of E. faecium with an MIC of 64 mg/L [20]. The 
improved current results probably reflect use of the 
1992 NCCLS revised procedure. In our survey, the 
automated systems performed well and we did not 
confirm an earlier finding [27] that the Vitek GPS-TA 
card exhibited only 72% sensitivity for the detection of 
vancomycin resistance. Lack of sensitivity was thought 
to be due to insufficient growth in the wells. The 
improved performance of the automated systems in our 
survey may be due to recognition of this problem as 
well as the use of revised sofcware for the Vitek system. 
Our experience may be strain specific, given the claim 
[28] that version 8.1 of the software cannot adequately 
detect all strains of enterococci exhibiting vancomycin 
resistance. However, in a recent LPTP survey using a 
vancomycin-resistant strain of E. faecalis (MIC 64 
mg/L), only two of 149 laboratories failed to detect the 
resistance; of these, one used Vitek and the other disk 
diffusion. The addition of the new screening well in the 
Vitek GPS card may have further enhanced the ability 
of this system to detect low-level vancomycin 
resistance. The Microscan positive breakpoint combo 
type 6 panel is reported to have 100% sensitivity in 
detecting vancomycin resistance of enterococci (MIC 
2 3 2  mg/L) [29]. Three Microscan users in our con- 
joint survey did report an intermediate result. Since the 
MIC was borderline, an intermediate result was con- 
sidered to be a minor error with no clinical significance. 
In Ontario, the Microbiology Committee endea- 
vors, through Committee Comments that accompany 
the results of each survey, and through other educa- 
tional vehicles such as the LPTP Newsletter, to alert 
participating laboratories about changes in NCCLS 
documents on antimicrobial susceptibility testing. 
Participants are required to adhere to NCCLS criteria 
when selecting and reporting antimicrobial results on 
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survey challenges. New breakpoints for vancomycin 
were established by the NCCLS in 1992 for testing 
enterococci by disk diffusion. Our results may reflect 
adherence to older standards by some participating 
laboratories. The failure of a minority of laboratories 
to detect the resistance when testing by disk diffusion 
may have been due to incubating the plates for less than 
a full 24 h. Some laboratories appear to have missed the 
small colonies or light film of growth within the zone 
of inhibition. 
The failure of laboratories to detect low-level 
resistance to vancomycin has raised concern that the 
true prevalence of such strains may be underestimated, 
given a report of 14% glycopeptide-resistant entero- 
cocci from intensive care unit patients in the USA [2]. 
In Canada, VRE were unusual at the time of our 1994 
survey (unpublished data), but recent epidemiologic 
studies indicate that such strains are now well established 
[30]. We have demonstrated that clinical microbiology 
laboratories in much of the country are able to detect 
low-level resistance mediated by the uanB gene and that 
performance is comparable across the country. Screen- 
ing for vancomycin resistance in enterococci by using 
the vancomycin-containing BHI agar plate has been 
recommended by the NCCLS [31]. 
In 1997, the LPTP and CMPT used a different 
type of challenge (unpublished data) to follow up and 
reassess the ability of laboratories to detect VRE. The 
CMPT used a simulated urine sample yielding a mixed 
growth of bacteria, including a vancomycin-resistant 
strain of E. faecium (MIC 64 mg/L). The LPTP sub- 
mitted a simulated fecal specimen with normal bowel 
flora and a vancomycin-resistant strain of E. faerium of 
the Vad3 phenotype (MIC 32 mg/L). The associated 
clinical histories indicated that the samples came from 
patients with a hgh  risk of carrying VRE. The 
expectation was that participating laboratories would 
screen for, and be able to detect, these resistant 
organisms. Less than 1% of laboratories that correctly 
identified their enterococcal isolates failed to detect the 
vancomycin resistance. Those laboratories that failed to 
screen for VRE, or failed to identify enterococcal 
isolates to the correct species, were classified as having 
unsatisfactory performance and advised to amend their 
procedures. 
Induction of the expression of vancomycin 
resistance, in at least some VanA and Vad3 strains, is 
associated with an increased susceptibdity or tolerance 
to penicillin [32-341, but the isolate of strain D366 in 
our survey was penicillin resistant under recommended 
susceptibility testing conditions. Only eight of the 258 
participants reporting a penicilbn result failed to obtain 
the correct result, and, since the method code was not 
recorded by six of these, we are not able to comment 
on method dependency. Enterococci may be resistant 
to penicillin and ampicillin due to either the pro- 
duction of low-affinity penicillin-bindmg proteins or 
the production of P-lactamase. E. faecium, strain D366, 
does not produce p-lactamase, However, only 66% of 
LPTP participants tested for the enzyme, whereas 93% 
of CMPT laboratories did so using a nitrocefin-based 
test. 
The greatest challenge to both participant and 
reference laboratories was detection of the borderline 
ampicillin resistance. Microscan users reported the 
greatest percentage of discordant susceptible results 
(88%) followed by Vitek (46%) and the breakpoint agar 
dilution (46%) methods. Lack of sensitivity of the 
Microscan panels and lack of specificity of the Vitek 
cards to detect ampicillin resistance have been noted 
previously [6,20]. The disk diffusion method was the 
most reliable at detecting the ampicillin resistance, 
although 19% of participating laboratories did report a 
falsely susceptible result. It is unlikely that the 
difficulties previously reported [19] due to the use of 
&sks with varying ampicdhn content played a role in 
the present discordant results, since participants are 
required to follow the NCCLS standards for all 
conditions of testing, including the Ask potency and the 
interpretive zone sizes. A 1989 College of American 
Pathologists (CAP) proficiency testing survey [18] 
reported similar performance for laboratories challenged 
with a strain of E. faecium having increased resistance 
to ampicillin. Eighty-three per cent of commercial 
broth microdilution MIC systems failed to detect the 
resistance in this study, while only 12% of disk diffusion 
users failed to do so. The results reported by parti- 
cipating laboratories in our survey do not confirm an 
earlier report that disk diffusion susceptibhty testing 
has 100% sensitivity and specificity for the detection of 
ampicillin resistance [32]. However, the methodology 
for disk diffusion testing in ths  study was different and 
the comparison may not be valid. 
The NCCLS recommends testing and reporting 
either penicillin or ampicillin and states that penicdin 
susceptibility may be used to predict the susceptibility 
to ampicifin. The converse is not necessarily true. A 
22-year review of p-lactam resistance in isolates of this 
species [35] confirms the reports of others that MICs 
are generally one log2 dht ion  lower for ampicillin 
when compared to penicillin. E. faecium strains are 
inherently more resistant to penicillin than are strains 
of E. faecalis, with usual MICs of 16-32 mg/L and 2-4 
mg/L respectively [36]. For strains exhibiting borderline 
resistance to penicillin (MIC 16 mg/L), an ampicfin 
MIC one two-fold dilution lower (8 mg/L) would 
result in a susceptible report and an incorrect prediction 
of the penicillin result. Therefore, we suggest that 
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penicillin rather than ampicillin should be used for 
definitive susceptibility testing of known isolates of 
E. faecium. This suggestion does not apply to E. fdecalis, 
since ampicillin remains the preferred agent for 
susceptibility testing of this species. 
Most enterococci showing Vad-type resistance to 
vancomycin remain susceptible to teicoplanin [37]. 
Therapeutic use of this agent appears to have been 
associated with the emergence of genetically unrelated 
strains of ampicillin-resistant enterococci in one 
hospital [38]. Since the use of teicoplanin is likely to 
increase, laboratories must be capable of accurately 
detecting ampicillin resistance to support effective 
therapy and to limit the nosocomial spread of such 
resistant strains. 
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